Research programme: mitochondrial Complex I disease therapies - Edison Pharmaceuticals

Drug Profile

Research programme: mitochondrial Complex I disease therapies - Edison Pharmaceuticals

Alternative Names: EPI B0001; EPI C0001; EPI-761

Latest Information Update: 23 Jul 2008

Price : $50

At a glance

  • Originator Edison Pharmaceuticals
  • Class
  • Mechanism of Action Electron transport complex I modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Friedreich's ataxia; MELAS syndrome; Optic atrophy

Most Recent Events

  • 14 Jul 2008 A lead compound from this programme, has entered clinical development
  • 05 Oct 2006 Preclinical trials in Optic atrophy in Brazil (unspecified route)
  • 28 Oct 2005 Preclinical trials in MELAS syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top